Mind the gap from research laboratory to clinic: Challenges and opportunities for next-generation assays in human diseases.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
31 08 2021
Historique:
received: 14 01 2021
revised: 24 07 2021
accepted: 26 07 2021
pubmed: 10 8 2021
medline: 24 8 2021
entrez: 9 8 2021
Statut: ppublish

Résumé

Modern vaccinology has experienced major conceptual and technological advances over the past 30 years. These include atomic-level structures driving immunogen design, new vaccine delivery methods, powerful adjuvants, and novel animal models. In addition, utilizing advanced assays to learn how the immune system senses a pathogen and orchestrates protective immunity has been critical in the design of effective vaccines and therapeutics. The National Institute of Allergy and Infectious Diseases of the National Institutes of Health convened a workshop in September 2020 focused on next generation assays for vaccine development (Table 1). The workshop focused on four critical pathogens: severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and human immunodeficiency virus (HIV)-which have no licensed vaccines-and tuberculosis (TB) and influenza-both of which are in critical need of improved vaccines. The goal was to share progress and lessons learned, and to identify any commonalities that can be leveraged to design vaccines and therapeutics.

Identifiants

pubmed: 34366145
pii: S0264-410X(21)00964-6
doi: 10.1016/j.vaccine.2021.07.071
pmc: PMC8343370
pii:
doi:

Types de publication

Clinical Conference Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

5233-5239

Subventions

Organisme : NIAID NIH HHS
ID : UM1 AI068618
Pays : United States

Informations de copyright

Copyright © 2021.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Clin Microbiol Rev. 2019 Oct 30;33(1):
pubmed: 31666281
mBio. 2021 Feb 16;12(1):
pubmed: 33593976
Cell Host Microbe. 2017 Aug 9;22(2):207-216
pubmed: 28799906
Immunity. 2019 Aug 20;51(2):398-410.e5
pubmed: 31350180
J Immunol. 2016 Aug 1;197(3):983-93
pubmed: 27342848
PLoS Pathog. 2021 Jul 6;17(7):e1009278
pubmed: 34228762
J Immunol. 2016 Aug 1;197(3):994-1002
pubmed: 27335502
Ann Intern Med. 2021 Feb;174(2):221-228
pubmed: 33090877
Nucleic Acids Res. 2019 Jan 8;47(D1):D339-D343
pubmed: 30357391
Immunity. 2019 Jan 15;50(1):241-252.e6
pubmed: 30552025
Lancet Respir Med. 2016 Mar;4(3):213-24
pubmed: 26907218
N Engl J Med. 2021 Mar 18;384(11):1003-1014
pubmed: 33730454
Immunity. 2018 Aug 21;49(2):288-300.e8
pubmed: 30097292
Nat Med. 2019 Apr;25(4):547-553
pubmed: 30936546
Lancet. 2018 Jul 21;392(10143):232-243
pubmed: 30047376
Science. 2021 Jan 8;371(6525):
pubmed: 33214287
Cell. 2019 Dec 12;179(7):1636-1646.e15
pubmed: 31787378
Antiviral Res. 2015 Nov;123:5-14
pubmed: 26304704
PLoS Pathog. 2019 Dec 3;15(12):e1008121
pubmed: 31794588
Nature. 2020 Jan;577(7788):95-102
pubmed: 31894150
J Virol. 2020 Feb 28;94(6):
pubmed: 31896599
Nat Med. 2020 Apr;26(4):618-629
pubmed: 32094927
PLoS One. 2017 Oct 24;12(10):e0186998
pubmed: 29065175
Nat Biotechnol. 2014 Feb;32(2):146-8
pubmed: 24441472
Science. 2020 May 29;368(6494):948-950
pubmed: 32393526
Proc Natl Acad Sci U S A. 2020 Sep 15;117(37):22920-22931
pubmed: 32873644
Immunity. 2021 Apr 13;54(4):753-768.e5
pubmed: 33765435
Cell Rep. 2016 Nov 22;17(9):2195-2209
pubmed: 27880897
Vaccine. 2015 Dec 10;33(50):7075-82
pubmed: 26424605
Sci Rep. 2022 Jan 18;12(1):889
pubmed: 35042868
J Oral Pathol. 1986 Jul;15(6):352-8
pubmed: 3093654
Science. 2020 Sep 4;369(6508):1210-1220
pubmed: 32788292
Cell. 2020 Aug 20;182(4):828-842.e16
pubmed: 32645326
iScience. 2021 Jan 09;24(2):102047
pubmed: 33554060
PLoS Pathog. 2020 Mar 12;16(3):e1008377
pubmed: 32163525
Nat Methods. 2017 Apr;14(4):395-398
pubmed: 28192419
Lancet Microbe. 2020 Nov;1(7):e283-e289
pubmed: 33015652
Immunity. 2015 Dec 15;43(6):1199-211
pubmed: 26682989

Auteurs

M Patricia D'Souza (MP)

Vaccine Clinical Research Branch, Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA. Electronic address: pdsouza@niaid.nih.gov.

Amy C Palin (AC)

Vaccine Clinical Research Branch, Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA.

Thomas Calder (T)

Office of the Director, Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA.

Hana Golding (H)

Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Steven H Kleinstein (SH)

Interdepartmental Program in Computational Biology and Bioinformatics, Yale University, New Haven, CT, USA; Department of Pathology and Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.

Erin L Milliken (EL)

NOVA Research Company, Silver Spring, MD, USA.

David O'Connor (D)

Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USA.

Georgia Tomaras (G)

Duke Human Vaccine Institute, Duke University, Durham, NC, USA.

Jon Warren (J)

Pre-clinical Research and Development Branch, Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA.

Cesar Boggiano (C)

Pre-clinical Research and Development Branch, Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH